Table 1.
Pathological Findings For Each Of The Samples Included In This Study. Disease Staging And Other Characteristics Listed Here Were Reported By An Independent Pathologist Who Evaluated The Tumor Sections Post-resection. Positive Or Negative Protein Expression Was Evaluated By Immunohistochemistry
| Lymph Gland | Nerve Infiltration | Vascular Tumor Throbus | Staging | Class | Sample Included | EGFR | HER-2 | C-erbB-2 | P53_Positive | Ki67_Positive | CgA | Syn | CD56 | PMS2 | MLH1 | MSH2 | MSH6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (9/13) | (+) | (+) | Ⅲc(T3N2bMx) | Mucinous | D | (−) | (−) | 40%+ | 50%+ | ||||||||
| (4/21) | (−) | (+) | Ⅲc(T4N2Mx) | Mucinous | D | (−) | (−) | (−) | 20%+ | ||||||||
| (7/25) | (−) | (−) | Ⅲc(T4N2Mx) | Mucinous | D | (−) | (−) | (−) | 50%+ | ||||||||
| (15/21) | (−) | (−) | Ⅲc(T3N2Mx) | Mucinous | D | (−) | (−) | 80%+ | 60%+ | ||||||||
| (2/15)Cancer nodule：1 | (−) | (−) | Ⅲb(T3N1cMx) | Mucinous | D | (−) | (−) | (−) | 30%+ | ||||||||
| (5/21)Cancer nodule：2 | (−) | (+) | Ⅲc(T3N2Mx) | Mucinous | D | (−) | (−) | 70%+ | 60%+ | ||||||||
| (1/19) | (−) | (+) | Ⅲb(T3N1Mx) | Mucinous | D | (+) | (−) | 5%+ | 30%+ | ||||||||
| (22/27)Cancer nodule：2 | (−) | (+) | Ⅲc(T3N2bMx) | Mucinous | D | Very few(+) | (−) | 80%+ | 70%+ | ||||||||
| (1/12) | (−) | (−) | Mucinous | D | (+++) | 75%+ | |||||||||||
| (10/13) | (−) | (+) | Ⅲc(T3N2Mx) | Mucinous | D | (−) | (−) | (−) | 40%+ | ||||||||
| (0/12) | (−) | (−) | Ⅱa(T3N0Mx) | Mucinous | D | (+) | (1+) | 10%+ | 60%+ | ||||||||
| (0/12) | (−) | (−) | Ⅱa(T3N0Mx) | Mucinous | D | (−) | (−) | 50%+ | 60%+ | ||||||||
| (14/22) | (+) | (+) | Ⅱc(T3N2bMx) | Mucinous | D | (−) | (−) | 90%+ | 70%+ | ||||||||
| (0/23) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 90%+ | 70%+ | ||||||||
| (0/13) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 80%+ | 60%+ | ||||||||
| (0/19) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | (−) | 20%+ | ||||||||
| (0/13) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | (−) | 70%+ | ||||||||
| (0/26) | (−) | (−) | Ⅱb(T4N0Mx) | StageII | A | Very few(+) | (1+) | 90%+ | 20%+ | ||||||||
| (0/21) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | Part of them(+) | (+) | (−) | 60%+ | ||||||||
| (0/16) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (1+) | 90%+ | 40%+ | ||||||||
| (0/25) | (−) | (−) | Ⅱb(T4N0Mx) | StageII | A | (−) | (−) | (−) | 60%+ | ||||||||
| (0/25) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 30%+ | 20%+ | ||||||||
| (0/16) | (+) | (+) | Ⅱa(T3N0Mx) | StageII | A | Very few(+) | (−) | 60%+ | 30%+ | ||||||||
| (0/33) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 90%+ | 80%+ | ||||||||
| (0/28) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | Very few(+) | (−) | 70%+ | 40%+ | ||||||||
| (0/23) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 90%+ | 80%+ | ||||||||
| (0/25) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 90%+ | 70%+ | ||||||||
| (0/13) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 30%+ | 60%+ | ||||||||
| (0/13) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 70%+ | 50%+ | ||||||||
| (0/17) | (+) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 90%+ | 70%+ | ||||||||
| (0/14) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (−) | 80%+ | 70%+ | ||||||||
| (0/14) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | Very few(+) | (1+) | 50%+ | 30%+ | (+) | (+) | (+) | (+) | ||||
| (0/19) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | Very few(+) | (−) | 60%+ | 60%+ | ||||||||
| (0/19) | (−) | (−) | Ⅱa(T3N0Mx) | StageII | A | (−) | (1+) | 70%+ | 60%+ | ||||||||
| (2/15) | (−) | (−) | Ⅲa(T2N1Mx) | StageIII | B | (−) | (−) | 80%+ | 40%+ | (+) | (+) | (+) | (+) | ||||
| (4/15) | (−) | (+) | Ⅲb(T3N2Mx) | StageIII | B | (−) | (1+) | (−) | 40%+ | ||||||||
| (7/12) | (−) | (+) | Ⅲc(T3N2Mx) | StageIII | B | (−) | (2+) | 80%+ | 40%+ | ||||||||
| (1/19) | Ⅲb(T3N1aMx) | StageIII | B | ||||||||||||||
| (1/19)Cancer nodule: 3 | (+) | (+) | Ⅲb(T3N1cMx) | StageIII | B | (−) | (2+) | 90%+ | 70%+ | ||||||||
| (7/14)Cancer nodule: 2 | (+) | (+) | Ⅲc(T3N2bMx) | StageIII | B | (−) | (−) | 90%+ | 40%+ | ||||||||
| (1/17) | (−) | (+) | Ⅲb(T3N1Mx) | StageIII | B | (−) | (−) | 70%+ | 70%+ | ||||||||
| (5/23) | (−) | (+) | Ⅲb(T3N2aMx) | StageIII | B | (−) | (−) | 90%+ | 70%+ | ||||||||
| (1/25) | (−) | (+) | Ⅲb(T3N1Mx) | StageIII | B | (−) | (−) | 1%+ | 40%+ | ||||||||
| (1/14) | (−) | (+) | Ⅲb(T3N1Mx) | StageIII | B | (−) | (1+) | 60%+ | 20%+ | ||||||||
| (7/14) | (−) | (-) | Ⅲc(T3N2Mx) | StageIII | B | Very few(+) | (−) | 90%+ | 70%+ | ||||||||
| (5/16) | (−) | (+) | Ⅲb(T3N2Mx) | StageIII | B | (−) | (1+) | (−) | 60%+ | ||||||||
| (1/34) | (−) | (+) | Ⅲb(T3N1Mx) | StageIII | B | (2+) | 90%+ | 30%+ | |||||||||
| (9/13) | (−) | (+) | Ⅲc(T3N2bMx) | StageIII | B | Very few(+) | (−) | 80%+ | 20%+ | ||||||||
| (2/18) | (−) | (−) | Ⅲb(T3N1bMx) | StageIII | B | (−) | (−) | (−) | 60%+ | ||||||||
| (13/30) | (−) | (−) | Ⅲc(T3N2Mx) | StageIII | B | (1+) | (3+) | 90%+ | 60%+ | ||||||||
| (0/13)Cancer nodule: 3 | (+) | (−) | Ⅲb(T3N1cMx) | StageIII | B | (−) | (−) | 30%+ | 40%+ | ||||||||
| (1/21) | (−) | (−) | Ⅲb(T3N1aMx) | StageIII | B | (−) | (−) | 60%+ | 60%+ | ||||||||
| (1/18) | (−) | (+) | Ⅲa(T2bN1aMx) | StageIII | B | Very few(+) | (−) | 90%+ | 50%+ | ||||||||
| (8/12) | (−) | (−) | Ⅲc(T3N2Mx) | StageIII | B | (−) | (-) | 70%+ | 80%+ | ||||||||
| (2/16)Cancer nodule: 2 | (−) | (−) | Ⅲb(T3N2Mx) | StageIV | C | (−) | (1+) | 70%+ | 60%+ | ||||||||
| (0/21) | (−) | (−) | Ⅱa(T3N0Mx) | StageIV | C | (−) | (2+) | 10%+ | 70%+ | ||||||||
| (1/19) | (−) | (+) | Ⅲb(T3N1Mx) | StageIV | C | (−) | (−) | (−) | 30%+ | ||||||||
| (5/15)Cancer nodule: 4 | (+) | (+) | Ⅳ(T3N2aM1) | StageIV | C | (−) | (−) | 30%+ | 60%+ | ||||||||
| (0/32) | (+) | (+) | Ⅳ(T3N0M1) | StageIV | C | (−) | (−) | 70%+ | 50%+ | ||||||||
| (0/26) | (+) | (−) | Ⅱa(T3N0Mx) | StageIV | C | (−) | (−) | (−) | 30%+ | ||||||||
| (2/24) | (−) | (−) | Ⅲb(T3N1Mx) | StageIV | C | Very few(+) | (−) | 80%+ | 70%+ | ||||||||
| (5/15) | (+) | (−) | Ⅲb(T3N2Mx) | StageIV | C | Very few(+) | (1+) | 80%+ | 30%+ | ||||||||
| (0/26) | (−) | (−) | Ⅳ(T3N0M1) | StageIV | C | (−) | (−) | 70%+ | 60%+ | ||||||||
| (0/16) | (−) | (−) | Ⅱa(T3N0Mx) | StageIV | C | (−) | (−) | 70%+ | 70%+ | ||||||||
| (5/14) | (−) | (−) | Ⅲb(T3N2Mx) | StageIV | C | (−) | (−) | 80%+ | 70%+ | ||||||||
| (10/20) | (−) | (+) | Ⅲc(T3N2bMx) | StageIV | C | (+) | (3+) | 20%+ | 40%+ | ||||||||
| (0/15) | (−) | (−) | Ⅱ(T4N0Mx) | StageIV | C | (−) | (−) | 20%+ | 20%+ | ||||||||
| (0/12) | (+) | (−) | Ⅳ(T3N0M1) | StageIV | C | (−) | (3+) | 30%+ | 30%+ | ||||||||
| (12/16) | (−) | (+) | Ⅲc(T3N2Mx) | StageIV | C | Part of them(+) | (1+) | 80%+ | 60%+ | ||||||||
| (14/17) | (+) | (+) | Ⅳ(T3N2bM1) | StageIV | C | Very few(+) | (−) | 40%+ | 30%+ | ||||||||
| (4/16) | (+) | (+) | Ⅳ(T3N2aM1) | StageIV | C | (−) | (2+) | 80%+ | 40%+ | ||||||||